High hs-CRP predicts PsO -> PsA? Abs#0484 #ACR23 @RheumNow 589 PsO pts wo PsA, followed mean 7.5 years 57 pts developed PsA (1.2 events/yr) Higher levels of b/l hs-CRP seen w: arthrlalgia, obesity, females Higher hs-CRP ass. w/ PsA - p=0.002, but HR only 1.03 (CI 1.01-1.05)

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/candida) & hepatic events No new signals... uveitis flares is interesting Need H2H of IL17's! IXE vs SEC vs BIM @RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA

Deucravacitinib (TYK2) data has been surprisngly good in SLE Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL Probably my #1 draft pick for "drugs I'm buying right now" @RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp

There is a high concordance (84.4%) of physician and patient global assessment of psoriatic arthritis disease activity from 538 paired assessments in the ARLAR multinational study, Maroof A et al, Abst #0506 #ACR23 @RheumNow https://t.co/NsT4MNWPVX https://t.co/TfuMj8qMXz

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE COMPLETE ➡️ TNFi failures ➡️Phase III, 400 pts, bimekizumab, PBO ➡️ Wk 16: improvements in joint and skin #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE OPTIMAL ➡️ tx-naive ➡️Phase III, 852 pts, bimekizumab, PBO, ADA ➡️ Wk 16: same as ADA for joints, BETTER FOR SKIN #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Brepocitinib ➡️ Tyk-2 inhibitor: IL12/23 & type I IFN ➡️ Phase Ib, 218 pts, 8% TNFi failure ➡️ 71% on concurrent MTX ➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52 #ACR23 @RheumNow

Love teaching about the PsA-AxSpa-IBD venn diagram of disease manifestations Interesting idea, using fecal calprotectin to trigger colonoscopy in pts w/PsA/axSpA ~40% w/pathologic finding, 4.4% dx w/IBD Jives w/my clinical experience @RheumNow #ACR23 Abstr0495 #ACRBest https://t.co/rIQpJnup9v

Kudos @AlexisOgdie & co for their work in this area Given proliferation of database research for causal inference, super important to have validated criteria to identify diseases Many spaces (looking at you sarcoidosis) where this is almost entirely absent @RheumNow #ACR23 https://t.co/krkgWAhjMr